{
  "docId": "019de071-753f-7227-aa1d-36a319c59353",
  "docSlug": "7013d0966bfedd0d757b9fa24a480455",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 34,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide highlights PFS, ORR, OS, and safety profile metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/17",
  "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353",
  "deckJsonHref": "/decks/019de071-753f-7227-aa1d-36a319c59353.json",
  "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "callout",
      "text": "These data support T-DXd becoming the standard of care for 2L HER2-positive mBC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaf95f34-aab7-4537-8f35-9b81a828987c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "mBC, metastatic breast cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b53a388a-6c03-4629-a2a5-fc793ebe5adf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.51,
        "x": 0.03,
        "y": 0.52
      },
      "kind": "list",
      "text": "Encouraging OS trend at the time of first interim analysis. 12-month OS rate for T-DXd was 94.1% vs 85.9% for T-DM1.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2224cd36-4af0-4c58-b19a-8a5437f5c040",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.95,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "list",
      "text": "Highly clinically meaningful and statistically significant improvement in PFS compared with T-DM1 in patients with HER2-positive mBC. PFS HR of 0.28 (P = 7.8 × 10-22). Consistent benefit seen across key subgroups and efficacy endpoints.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37e7c702-a772-4808-b901-b466731847ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.55,
        "x": 0.03,
        "y": 0.67
      },
      "kind": "list",
      "text": "A safety profile that is comparable between the two arms. Similar rates of all grade and grade ≥3 drug-related TEAEs between arms. There were no grade 4 or 5 ILD/pneumonitis events in either arm.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2be175f-face-4642-bee9-ce3c82fa853f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.84,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "In the first randomised Phase III trial in breast cancer, T-DXd demonstrated:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ba879ab-962d-422f-bd3c-14c94edfaf4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.23,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f06137ea-5494-44dc-bd97-11d38aebfae5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 17,
      "beatId": "b84365e9-a163-4557-b2fe-beb8ac4c4175",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Key takeaways and future prospects for Enhertu",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f6f774ca-af54-4b25-aa3a-3b940b789d31",
      "evidence": "The deck highlights the limitations of current treatments and Enhertu's potential to improve patient outcomes.",
      "position": 0,
      "objective": "What are the consequences of not adopting Enhertu as the standard of care?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}